Reuben Harris on How Tamoxifen Resistance May be Driven by APOBEC3B

Reuben S. Harris, PhD
Published: Thursday, Dec 10, 2015



Reuben S. Harris, PhD, investigator, Howard Hughes Medical Institute, professor, Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota College of Biological Sciences, explains the role APOBEC3B may play in tamoxifen resistance in ER-positive breast cancer.

APOBEC3B, an anti-viral enzyme, was investigated in a retrospective study using a large cohort that was available for analysis from a Dutch study. Harris and his team looked at the primary tumor specimens, determined how high or low the APOBEC3B was expressed, and then stratified this data for recurrent disease outcome overtime.

They found that patients with high levels of APOBEC3B had much worse outcomes compared to those with low levels. Within 1 year, most of those with high levels of APOBEC3B experienced disease recurrence and tamoxifen resistance. Disease progression and resistance to tamoxifen was significantly less common in those with low levels of APOBEC3B, says Harris.

<<< View more from the 2015 San Antonio Breast Cancer Symposium



Reuben S. Harris, PhD, investigator, Howard Hughes Medical Institute, professor, Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota College of Biological Sciences, explains the role APOBEC3B may play in tamoxifen resistance in ER-positive breast cancer.

APOBEC3B, an anti-viral enzyme, was investigated in a retrospective study using a large cohort that was available for analysis from a Dutch study. Harris and his team looked at the primary tumor specimens, determined how high or low the APOBEC3B was expressed, and then stratified this data for recurrent disease outcome overtime.

They found that patients with high levels of APOBEC3B had much worse outcomes compared to those with low levels. Within 1 year, most of those with high levels of APOBEC3B experienced disease recurrence and tamoxifen resistance. Disease progression and resistance to tamoxifen was significantly less common in those with low levels of APOBEC3B, says Harris.

<<< View more from the 2015 San Antonio Breast Cancer Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x